Ramón Salazar *

Autor invitado por SIIC

Los datos aquí expuestos abren un nuevo camino para el tratamiento del cáncer neuroendocrino.

NUEVAS OPCIONES DE TRATAMIENTO COMBINADO INHIBIDOR DE LA VIA DE MTOR EN TUMORES NEUROENDOCRINOS

El cáncer neuroendocrino es una patología para la que se dispone sólo de tratamientos paliativos. La quimioterapia tradicional sólo es efectiva en los TNE pancreáticos y las respuestas acostumbran a ser limitadas. Los inhibidores mTOR se presentan como una molécula prometedora en la reducción y/o estabilización del tumor neuroendocrino.

*Ramón Salazar
describe para SIIC los aspectos relevantes de su trabajo
POTENTIAL SYNERGIES FOR COMBINED TARGETED THERAPY IN THE TREATMENT OF NEUROENDOCRINE CANCER
Institución principal de la investigación
*Institut Català D'oncologia, Barcelona, España
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
Eriksson B, Klöppel G, Krenning E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: well differentiated jejunal–ileal tumor/carcinoma. Neuroendocrinology 2008; 87:8–19.

Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC and Meric-Bernstam F. Antitumor activity of rapamycin and octeotride as single agents or in combination in neuroendocrine tumours. Endocrine-Related Cancer, 2008; 15:257-266.

Rinke A, Müller H, Schade-Brittinger C, Klose K, Barth P, et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group. JCO 2009; 27 (28):4656-4663.

Stephan Wullschleger, Robbie Loewith and Michael N. Hall. TOR Signaling in Growth and Metabolism. Cell 2006; 124:471-484. [doi 10.1016/j.cell.2006.01.016].

Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5 (8): 671-88.

Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. JCO 2009; 27 (13): 2278-87.

Salazar R., Reidy-Lagunes D., and Yao J. Potential Synergies for Combined Targeted Therapy in the Treatment of Neuroendocrine Cancer. Drugs, 2011; 71(7):841-852.

Albanell J, Dalmases A, Rovira A and Rojo F. mTOR signaling in human cancer. Clinical Translational Oncology 2007; 9:484-93.

Shida T, Kishimoto T, Furuya M, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 2010; 65: 889-93.

James C. Yao, M.D., Manisha H. Shah et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med 2011; 364:514-23.

Pavel M, Hainsworth JD, Baudin E et al. A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide LAR versus placebo + octreotide LAR in patients with advanced neuroendocrine tumors (RADIANT-2). Ann Oncol 2010, 21 (suppl 8): viii4 (LB A8) [doi:10.1093/annonc/mdq601].

James C. Yao, Catherine Lombard-Bohas, Eric Baudin, et al. Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial. JCO 2010; 29(1):69-76.

von Wichert G, Jehle PM, Hoeflich A, et al. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res, 2000; 60:4573-4581.

Otros artículos de Ramón Salazar

Salazar R, Wiedenmann B, Rindi G, Ruzsinewski P. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. Neuroendocrinology, 2011 Dec 23. [Epub ahead of print]

Salazar R., Reidy-Lagunes D., and Yao J. Potential Synergies for Combined Targeted Therapy in the Treatment of Neuroendocrine Cancer. Drugs, 2011; 71(7):841-852.

Capdevila J, Salazar R, Halperín I, Abad A, Yao JC. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev., 2011; 30 Suppl 1:27-34. Review.

Babel I, Barderas R, Diaz-Uriarte R, Moreno V, Suarez A, Fernandez-Aceñero MJ, Salazar R, Capellá G, Casal JI. Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol Cell Proteomics., 2011; 10(3):M110.001784.

Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, Glas AM, Van't Veer LJ, Tollenaar R. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol., 2011; 29(1):17-24.

Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, Salazar R, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology., 2009; 90(2):214-9.

Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol., 2008; 9(1):61-72. Review.

Vilar E, Salazar R, Perez-García J, Cortes J, Öberg K, and Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocrine-Related Cancer, 2007; 14:221–232.

Durán I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu L L, Yao J and Tabernero J. New drug development in digestive neuroendocrine tumors. Annals of Oncology, 2007; 18: 1307–1313.

Salazar R, Villabona C, Fabregat J. Gastrointestinal and pancreatic neuroendocrine tumors. Med Clin (Barc), 2006; 127(6):227-31. Review.

Para comunicarse con Ramón Salazar mencionar a SIIC como referencia:
ramonsalazar@iconcologia.net

---

Acerca del trabajo completo

NUEVAS OPCIONES DE TRATAMIENTO COMBINADO INHIBIDOR DE LA VIA DE MTOR EN TUMORES NEUROENDOCRINOS

Título original en castellano
POSIBLES SINERGIAS PARA LA TERAPIA DIRIGIDA COMBINADA EN EL TRATAMIENTO DE CANCER NEUROENDOCRINO

Autor
Ramón Salazar¹
1 Doctor en Medicina, Institut Català D'oncologia, Barcelona, España, Head. Early Clinical Research Unit; Head

Acceso a la fuente original
Drugs
http://link.springer.com/journal/40265

ua40317